Novo Nordisk said Thursday it was buying US biotech firm Akero Therapeutics, which is developing treatments for a number of metabolic diseases, for $4.7 billion.
This article was originally published on this website.
Novo Nordisk buys US biotech firm Akero for $4.7 billion
